Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : VOLTAIRE'S PORCH-MODERATED -- Ignore unavailable to you. Want to Upgrade?

To: jmanvegas who wrote (48585)	3/11/2002 5:14:30 PM
From: Jim Willie CB	Read Replies (1) \| Respond to of 65232

thanks, JManV... will check TRMS the chief research scientist of VAXGen is a guy who was involved in all the seminal work regarding retro-fitting protein layers upon new strain mutation discovery cannot think of his name but VAXGen's vaccine was in Phase3 back in the summer they wanted fasttrack approval, but were denied wanted ft approval due to "multiplier effect" I wonder what key scientific advantages will produce the first vaccine whoever is first wins in this race the Gates Foundation has promised $5-6 billion for a worldwide vaccination that is a lot of topline sales numbers (but they must each prove purchase of MSWindows latest release, JUST KIDDING) my understanding is the winner for HIV vaccine will very likely provide a cavalcade of other winners using the same research techniques e.g. herpes, malaria thanks for hanging around, this is very unlike you you getting soft ??? / jim